Hormonal
In obese patients with type 2 diabetes, GLP-1 receptor agonists significantly reduce the risk of major adverse cardiovascular events (MACE) compared to placebo, whereas SGLT-2 inhibitors show a non-significant trend.
If you have type 2 diabetes and are obese, GLP-1 receptor agonists (like liraglutide, semaglutide, or dulaglutide) have been proven to significantly lower your risk of major heart events compared to a placebo. SGLT-2 inhibitors also help but did not reach statistical significance in this specific obese subgroup analysis. Discuss GLP-1 RAs with your doctor as a first-line treatment for cardiovascular protection.
In T2DM patients with obesity, GLP-1 RAs significantly reduced the risk of MACE versus placebo (relative risk, RR [95% confidence interval, CI]: 0.88 [0.81–0.96]), whereas SGLT-2 inhibitors showed a tendency (RR [95% CI]: 0.91 [0.83–1.00]).
Why this rating
Network meta-analysis of 12 high-quality RCTs with >100,000 participants, though indirect comparison limits direct head-to-head certainty.
Source
Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
Kazushi Uneda et al. · Scientific Reports · 2021
DOI 10.1038/s41598-021-89620-7
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →